Werewolf Therapeutics Q4 2025 Earnings Report

Werewolf Therapeutics EPS Results

• Actual EPS: -$0.20
• Consensus EPS: -$0.34
• Beat/Miss: Beat by +$0.14
• One Year Ago EPS: N/A

Werewolf Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.30 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Werewolf Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/27/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, April 1, 2026
• Conference Call Time: 9:30AM ET

Werewolf Therapeutics (NASDAQ:HOWL) (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs. These investigational agents are engineered to engage key immune pathways—such as T-cell activation and pro-inflammatory cytokine signaling—only when proteolytically processed by enzymes present in the tumor milieu. This approach is intended to drive a potent, localized immune response against cancer cells while reducing the risk of adverse events associated with systemic cytokine exposure.

The company’s pipeline spans both preclinical and early clinical stages, with lead programs targeting interleukin and tumor-necrosis factor family members. In addition to internal research efforts, Werewolf Therapeutics collaborates with academic institutions and industry partners to explore combination regimens that may further enhance the anti-tumor activity of its conditional agents.

Founded in 2019 and headquartered in Cambridge, Massachusetts, Werewolf Therapeutics is led by a management team with extensive experience in immuno-oncology drug discovery and clinical development. The company is focused on advancing its pipeline through regulatory milestones and clinical proof-of-concept studies in the United States.